A-SPINE Asia Co., Ltd.

NT$29.45As of Sun 8 Nov 2026, 12:00 UTC

TPEx:6758Healthcare

Country Taiwan

PE (Fwd) 23.15

TSR 7Y CAGR (9.87%)

Div yield —

ROE 5.53%

Medical Devices

Beta (5Y) —

PE TTM 26.43

TSR TTM (23.58%)

Mkt cap NT$396.7M

ROIC 5.25%

SE Grade™

—

Value

Quality

Moat

1Y Price

Reference

NT$30

3.56%

(42.90%)

Price above Reference Value

TTM

FYE 31 Dec TWD

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

448.8

RevenueNT$M

—

330.2

391.3

404.9

448.8

482.9

10.78%

—

10.83

Revenue growth%

—

18.51

3.50

10.83

7.61

10.83

—

74.07

Gross margin%

—

72.74

74.69

75.30

74.07

74.19

74.38

—

4.11

Operating margin%

—

2.39

2.84

1.93

4.11

4.14

2.61

—

3.36

Net margin%

—

2.43

2.35

2.08

3.36

2.39

—

26.43

P/E ratio (avg)x

—

64.68

56.45

68.35

33.42

24.60

60.56

—

25.46

EV/EBITx

—

73.52

54.22

84.55

31.28

22.14

63.87

—

7.07

FCF yield (avg)%

—

2.64

0.09

2.27

5.59

7.30

2.45

—

6.28

FCF margin%

—

4.14

0.12

3.22

6.28

6.03

3.68

—

1.868

FCF / Net incomex

—

1.706

0.053

1.550

1.868

1.796

1.628

—

5.25

ROIC%

—

2.33

3.19

2.19

5.25

5.86

2.76

—

5.53

Return on equity%

—

2.89

3.34

3.09

5.53

5.74

3.21

—

2.90

Return on assets%

—

1.57

1.79

1.66

2.90

3.03

1.73

—

1.11

EPSNT$

—

0.59

0.68

0.62

1.11

1.20

23.44%

—

78.98

EPS growth%

—

15.06

(8.67)

78.98

7.47

15.06

—

20.27

Bookvalue per shNT$

—

20.50

20.28

20.04

20.27

21.47

(0.37%)

—

2.08

FCF per shareNT$

—

1.01

0.04

0.96

2.08

2.15

27.23%

—

Dividend per shNT$

—

Div yield (avg)%

—

Payout ratio%

—

13.47

Shares (diluted)M

—

13.52

13.51

13.54

◌13.54

0.04%

—

(0.18)

Buyback yield%

—

0.05

(0.01)

(0.18)

◌—

(0.01)

—

0.472

D/E ratiox

—

0.522

0.497

0.491

0.472

0.445

0.494

—

469.6

Enterprise valueNT$M

—

580.0

601.8

659.8

576.9

442.4

(0.18%)

—

32.73

LT debtNT$M

—

49.09

43.64

64.58

32.73

(12.64%)

—

Peers (US$12.47M)

Cap (US$)

Health & Life Co., Ltd.

12.17M

—

DuoGenic StemCells…

11.03M

—

EPS Bio Technology…

10.35M

—

iTonic Holdings Ltd.

12.58M

—

Capital

TTM

10Y

Leveragex

2.340

2.828

EBIT/Intx

6.184

4.508

Own earn%

—

Sh yield%

(0.18)

(0.01)

Owners

Insiders/Inst%

0.57

9.39

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

4/4

Revenue growth years

3/3

EPS growth years

2/3

Dividend streakyrs

Op margin range%

2–4

$1 testx

−0.4

Incr. ROIC%

131

A-SPINE Asia Co., Ltd., a medical device company, engages in the research, development, manufacture, and marketing of spinal implants and instruments in Taiwan, China, the Philippines, Australia, New Zealand, Iran, Vietnam, Indonesia, Spain, Trinidad, and Sri Lanka.

Growth vs revenue

Latest

Trend

3Y CAGR

Rel growth

Revenue

NT$448.8M

10.78%

1.00×

Cost of revenue

NT$116.4M

8.95%

0.95×

Operating expenses

NT$314.0M

10.57%

0.99×

Asset mix

Trend

Other

88.43%

Cash and investments

10.89%

Goodwill & intangibles

0.67%

Reinvestment returns

4Y median

Trend

Reinvestment rate

(111.25%)

Return on capital

2.76%

Spread over hurdle

(0.46%)